Trial Profile
Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Solnatide (Primary)
- Indications Adult respiratory distress syndrome; Pulmonary oedema
- Focus Adverse reactions
- Sponsors APEPTICO Forschung und Entwicklung
- 09 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 09 Feb 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.
- 24 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.